Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Tuesday, Benzinga reports. They presently have a $327.00 price objective on the biotechnology company’s stock. Wedbush’s target price would suggest a potential upside of 24.32% from the company’s current price.
Several other research firms have also issued reports on ASND. BMO Capital Markets began coverage on Ascendis Pharma A/S in a research report on Tuesday, August 18th. They set an “outperform” rating and a $319.00 price target on the stock. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Barclays dropped their target price on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Evercore restated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Finally, Wells Fargo & Company lowered their price objective on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $307.65.
View Our Latest Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Trading Up 6.1%
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. On average, analysts anticipate that Ascendis Pharma A/S will post 3.9 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Jean Jacques Bienaime purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the acquisition, the director owned 2,900 shares in the company, valued at $714,357. The trade was a 222.22% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 40.00% of the company’s stock.
Institutional Trading of Ascendis Pharma A/S
Large investors have recently modified their holdings of the company. Cetera Investment Advisers bought a new position in Ascendis Pharma A/S in the 2nd quarter worth about $552,000. Rhumbline Advisers boosted its position in shares of Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after buying an additional 55 shares during the period. Daiwa Securities Group Inc. grew its holdings in Ascendis Pharma A/S by 66.2% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock worth $645,000 after buying an additional 1,488 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in Ascendis Pharma A/S by 83.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock worth $34,700,000 after buying an additional 91,412 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Ascendis Pharma A/S in the 2nd quarter valued at approximately $897,000.
Trending Headlines about Ascendis Pharma A/S
Here are the key news stories impacting Ascendis Pharma A/S this week:
- Positive Sentiment: Settlement and licensing agreement: Ascendis and BioMarin agreed to terms covering the sale of YUVIWEL and related navepegritide products. Investors appear to view the resolution of the disputes as a significant positive catalyst. Ascendis and BioMarin Enter Binding Term Sheet
- Positive Sentiment: Market reaction: Reports indicated that Ascendis shares rose about 6% following the BioMarin license and settlement announcement, highlighting the deal’s near-term importance to investors. Ascendis Pharma Shares Rise Over License Deal
- Neutral Sentiment: Analyst sentiment remains favorable: HC Wainwright maintained a Buy rating and a $345 price target, while the broader analyst average rating was also reported as Buy. Ascendis Pharma Receives Average Buy Rating
- Negative Sentiment: HC Wainwright cut estimates: The firm reduced its EPS forecasts for every listed period, including FY2027 to $11.25 from $11.88 and Q3 2026 to $1.09 from $1.16. The revisions suggest more cautious expectations for Ascendis’ earnings trajectory, although the Buy rating was retained.
- Negative Sentiment: Bank of America trimmed its target: BofA lowered its price objective to $304 from $306 but kept a Buy rating, creating a modestly negative signal alongside the earnings-estimate reductions. Bank of America Lowers Ascendis Price Target
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- 3 Space Stocks: Ready for Liftoff or Burning Up on Reentry?
- Space Race Meets Ground Reality for Tower REITs
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
